← Home
Otsuka Holdings 
Pharma / Pharmaceuticals, Healthcare
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-02-19 07:30:00 | Biodexa Licenses Phase 1 Ready Drug Candidate From Otsuka For Rare Stomach Cancer Mtx240’s mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (gist) meg flippin, benzinga staff writer cardiff, uk / access newswire / february 19, 2026 / biodexa pharmaceuticals plc (nasdaq:bdrx), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new phase 1 ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or gist. several drugs are available to treat gist, but all ultimately fail when the tumor develops resistance. |
| 2026-02-04 08:30:00 | Biodexa Announces Exclusive License Of Otsuka’s Opb-171775, A Potent Phase 1 Ready Molecular Glue For Gist February 4, 2026 biodexa announces exclusive license of otsuka’s opb-171775, a potent phase 1 ready molecular glue for gist novel mechanism of action shown to be effective in tki resistant pdx models cardiff, uk – february 4, 2026 – biodexa pharmaceuticals plc (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with otsuka pharmaceutical co., ltd (otsuka) for opb-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (gist). |
| 2025-11-10 08:00:00 | 4dmt Reports Third Quarter 2025 Financial Results, Operational Highlights And Expected Upcoming Milestones Entered strategic partnership with otsuka pharmaceutical co., ltd. for the development and commercialization of 4d-150 in the apac region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the phase 1/2 prism clinical trial in wet amd completed equity offering providing net proceeds of ~$93 million announced up to $11 million equity investment from the cystic fibrosis foundation to accelerate development of 4d-710 for cystic fibrosis into phase 2 $372 million in cash, cash equivalents and marketable securities as of september 30, 2025, combined with upfront and expected cost sharing from otsuka partnership and ~$93 million in net proceeds from equity offering, expected to fund currently planned operations into second half of 2028 emeryville, calif. |
| 2025-10-30 23:02:00 | 4dmt Announces Exclusive License Agreement With Otsuka Pharmaceutical Co., Ltd. For Development And Commercialization Of 4d-150 In Asia-pacific Emeryville, calif., oct. 30, 2025 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a strategic partnership with otsuka pharmaceutical co., ltd. (otsuka) to develop and commercialize 4d-150 for the treatment of wet age-related macular degeneration (wet amd) and diabetic macular edema (dme) in the greater asia-pacific (apac) region including japan. |
| 2025-09-19 08:00:00 | Esperion Partner Otsuka Receives Regulatory Approval To Market Nexletol® In Japan For The Treatment Of Hypercholesterolemia Third largest global market for cardiovascular prevention represents significant global growth opportunity for nexletol third largest global market for cardiovascular prevention represents significant global growth opportunity for nexletol |
📰 Browse additional press releases for Otsuka Holdings!
Sign up for free or log in✅ Download "The Checklist Value Investor — A Smarter Way to Pick Stocks" — totally free!